Review Article
Atrial Fibrillation: A Review of Recent Studies with a Focus on Those from the Duke Clinical Research Institute
Table 1
Baseline characteristics for novel oral anticoagulant trials.
| | RE-LY | ROCKET-AF | ARISTOTLE |
| Study drug | Dabigatran 150 mg twice daily | Rivaroxaban 20 mg daily | Apixaban 5 mg twice daily | Renal dose adjustment | Dabigatran 110 mg twice daily | Rivaroxaban 15 mg daily | Apixaban 2.5 mg twice daily | Average CHADS2 score | 2.2 | 3.5 | 2.1 | Mean age | 71 | 73 | 70 | Creatinine clearance >30, <50 ml/min | 19.4% | 20.8% | 15.2% | Creatinine clearance >50 ml/min | 80.6% | 79.2% | 83.4% | Prior warfarin use | 49.6% | 62.4% | 57.2% | Prior myocardial infarction | 16.6% | 17.3% | 14.2% | Prior stroke/TIA | 20.0% | 54.8% | 19.4% |
|
|